Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.

MLA

Harmanen, Minna, et al. “Real-World Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.” HemaSphere, vol. 7, no. 10, Sept. 2023, p. e954. EBSCOhost, https://doi.org/10.1097/HS9.0000000000000954.

APA

Harmanen, M., Klaavuniemi, T., Sorigue, M., Khan, M., Prusila, R., Kari, E., Alanne, E., Rajamäki, A., Sunela, K., Jukkola, A., Jantunen, E., Sancho, J.-M., Ketola, S., Kuitunen, H., Selander, T., Rönkä, A., & Kuittinen, O. (2023). Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria. HemaSphere, 7(10), e954. https://doi.org/10.1097/HS9.0000000000000954

Chicago

Harmanen, Minna, Tuula Klaavuniemi, Marc Sorigue, Madiha Khan, Roosa Prusila, Esa Kari, Erika Alanne, et al. 2023. “Real-World Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.” HemaSphere 7 (10): e954. doi:10.1097/HS9.0000000000000954.